Skip to main content
SpringerLink
Log in

Recent Advances in Cardiac Allotransplantation

  • Chapter
Surgical Management of Congestive Heart Failure

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Heart transplantation has become a routine approach to the management of severe cardiac failure (1). Indeed, given the excellent survival statistics for heart transplant recipients, heart transplant outcomes are now an important standard against which the success of other therapies is routinely measured. There are more than 200 institutions currently performing heart transplants worldwide, two-thirds of them in the United States. In 1995, there were 4049 heart transplants reported to the International Society for Heart and Lung Transplantation (ISHLT); 2359 of these took place in the United States. The same figures for the year 2000 were 3175 and 2197, respectively (2). It is clear that more patients would benefit from heart transplantation if more donor organs were available; in 2000, there were 3452 new registrations on US waiting lists, according to data from the United Network for Organ Sharing (UNOS). In that same year, the median waiting time for a heart transplant in the United States, considering all patients regardless of waiting list priority, was 346 days (3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hunt SA. Current status of cardiac transplantation. JAMA 1998;280:1692.

    Article  PubMed  CAS  Google Scholar 

  2. Hertz MI, Taylor DO, Trulock EP, et al. The Registry of the International Society for Heart and Lung Transplantation: 19th Official Report—2002. J Heart Lung Transplant 2002;21:950.

    Article  PubMed  Google Scholar 

  3. 2001 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry for Transplant Recipients: Transplant Data 1991–2000. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation; Richmond, VA: United Network for Organ Sharing; Ann Arbor, MI: University Renal Research and Education Association, Ann Arbor, MI.

    Google Scholar 

  4. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429.

    Google Scholar 

  5. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651.

    Article  PubMed  CAS  Google Scholar 

  6. Robbins RC, Barlow CW, Oyer PE, et al. Thirty years of cardiac transplantation at Stanford University. J Thorac Cardiovasc Surg 1999;117:939.

    Article  PubMed  CAS  Google Scholar 

  7. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778.

    PubMed  CAS  Google Scholar 

  8. Mudge GH, Goldstein S, Addonizio LJ, et al. Twenty-fourth Bethesda conference: cardiac transplantation: Task Force 3: recipient guidelines/prioritization. J Am Coll Cardiol 1993;22:21.

    PubMed  CAS  Google Scholar 

  9. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660.

    PubMed  CAS  Google Scholar 

  10. Cimato TR, Jessup M. Recipient selection in cardiac transplantation: contraindications and risk factors for mortality. J Heart Lung Transplant 2002;21:1161.

    Article  PubMed  Google Scholar 

  11. Blanche C, Blanche DA, Kearney B, et al. Heart transplantation in patients 70 years of age and older: a comparative analysis of outcome. J Thorac Cardiovasc Surg 2001;121:532.

    Article  PubMed  CAS  Google Scholar 

  12. Mancini D, Beniaminovitz A, Edwards N, et al. Survival of diabetic patients following cardiac transplant. J Heart Lung Transplant 2001;20:168.

    Article  PubMed  Google Scholar 

  13. Bourge RC, Kirklin JK, Naftel DC, et al. Predicting outcome after cardiac transplantation: lessons from the Cardiac Transplant Research Database. Curr Opin Cardiol 1997;12:136.

    Article  PubMed  CAS  Google Scholar 

  14. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992;19:48.

    Article  PubMed  CAS  Google Scholar 

  15. Stanek B, Sturm B, Frey B, et al. Bridging to heart transplantation: prostaglandin El vs prostacyclin vs dobutamine. J Heart Lung Transplant 1999;18:358.

    Article  PubMed  CAS  Google Scholar 

  16. Canver CC, Chanda J. Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates. Ann Thorac Surg 2000;69:1823.

    Article  PubMed  CAS  Google Scholar 

  17. Frey B, Zuckermann A, Koller-Strametz J, et al. Effects of continuous, long-term therapy with prostaglandin El preoperatively on outcome after heart transplantation. Transplant Proc 1999;31:80.

    Article  PubMed  CAS  Google Scholar 

  18. Yeoh TK, Frist WH, Lagerstrom C, et al. Relationship of cardiac allograft size and pulmonary vascular resistance to long-term cardiopulmonary function. J Heart Lung Transplant 1992;11:1168.

    PubMed  CAS  Google Scholar 

  19. Petrofski JA, Hoopes CW, Bashore TM, et al. Mechanical ventricular support lowers pulmonary vascular resistance in a patient with congential heart disease. Ann Thorac Surg 2003;75:1005.

    Article  PubMed  Google Scholar 

  20. Adamson RM, Dembitsky WP, Jaski BE, et al. Left ventricular assist device support of medically unresponsive pulmonary hypertension and aortic insufficiency. ASAIO J 1997;43:365.

    Article  PubMed  CAS  Google Scholar 

  21. Koerner MM, Tenderich G, Minami K, et al. Results of heart transplantation in patients with preexisting malignancies. Am J Cardiol 1997;79:988.

    Article  PubMed  CAS  Google Scholar 

  22. Goldstein DJ, Seldomridge A, Addonizio L, et al. Orthotopic heart transplantation in patients with treated malignancies. Am J Cardiol 1995;75:968.

    Article  PubMed  CAS  Google Scholar 

  23. Hosenpud JD, Pamidi SR, Fiol BS, et al. Outcomes in patients who are hepatitis B surface antigen-positive before transplantation: an analysis and study using the joint ISHLT/UNOS thoracic registry. J Heart Lung Transplant 2000;19:781.

    Article  PubMed  CAS  Google Scholar 

  24. Ko WJ, Chou NK, Hsu RB, et al. Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area. J Heart Lung Transplant 2001;20:865.

    Article  PubMed  CAS  Google Scholar 

  25. Nguyen MH, Wright TL. Therapeutic advances in the management of hepatitis B and hepatitis C. Curr Opin Infect Dis 2001;14:593.

    PubMed  CAS  Google Scholar 

  26. Fishman JA, Rubin RH. Solid organ transplantation in HIV-infected individuals: obstacles and opportunities. Transplant Proc 2001;33:1310.

    Article  PubMed  CAS  Google Scholar 

  27. Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003;348:2323–2328.

    Article  PubMed  Google Scholar 

  28. Abbas AK, Lichtman AH, Pober JS. Immune responses to tissue transplants. In: Abbas AK, Lichtman AH, Pober JS, eds. Cellular and Molecular Immunology, 2nd ed. WB Saunders, Philadelphia, PA: 1994.

    Google Scholar 

  29. Smith JD, Danskine AJ, Laylor RM, et al. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transplant Immunol 1993; 1:60.

    Article  CAS  Google Scholar 

  30. Baid S, Saidman SL, Tolkoff-Rubin M, et al. Managing the highly sensitized transplant recipient and B cell tolerance. Curr Opin Immunol 2001;13:577.

    Article  PubMed  CAS  Google Scholar 

  31. Betkowski AS, Graff R, Chen JJ, Hauptman PJ. Panel-reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant 2002;21:644.

    Article  PubMed  Google Scholar 

  32. Bishay ES, Cook DJ, Starling RC, et al. The clinical significance of flow cytometry crossmatching in heart transplantation. Eur J Cardiothorac Surg 2000;17:362.

    Article  PubMed  CAS  Google Scholar 

  33. Przybylowski P, Balogna M, Radovancevic B, et al. The role of flow cytometry-detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. Transplantation 1999;67:258.

    Article  PubMed  CAS  Google Scholar 

  34. Aziz S, Hassantash SA, Nelson K, et al. The clinical significance of flow cytometry crossmatching in heart transplantation. J Heart Lung Transplant 1998;17:686.

    PubMed  CAS  Google Scholar 

  35. McKenna DH Jr, Eastlund T, Segall M, et al. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant 2002;21:1218.

    Article  PubMed  Google Scholar 

  36. Massad MG, McCarthy PM, Smedira NG, et al. Does successful bridging with the implantable left ventricular assist device affect cardiac transplantation outcome? J Thorac Cardiovasc Surg 1996;112:1275.

    Article  PubMed  CAS  Google Scholar 

  37. Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 1997;64:1120.

    Article  PubMed  CAS  Google Scholar 

  38. Itescu S, Ankersmit J-H, Kocher AA, Schuster MD. Immunobiology of left ventricular assist devices. Prog Cardiovasc Dis 2000;43:67.

    Article  PubMed  CAS  Google Scholar 

  39. Stringham JC, Bull DA, Fuller TC, et al. Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. J Heart Lung Transplant 1999;18:160.

    Article  PubMed  CAS  Google Scholar 

  40. Ratkovec RM, Hammond EH, O’Connell JB, et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch—preliminary results with plasmapheresis. Transplantation 1992;54:651.

    Article  PubMed  CAS  Google Scholar 

  41. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999;18:701.

    Article  PubMed  CAS  Google Scholar 

  42. Ruiz JC, de Francisco AL, Vazquez de Prada JA, et al. Successful heart transplantation after anti-HLA antibody removal with protein-A immunoadsorption in a hyperimmunized patient. J Thorac Cardiovasc Surg 1994;107:1366.

    PubMed  CAS  Google Scholar 

  43. Robinson JA. Apheresis in thoracic organ transplantation. Ther Apher 1999;3:34.

    Article  PubMed  CAS  Google Scholar 

  44. Dowling RD, Jones JW, Carroll MS, Gray LA Jr. Use of intravenous immunoglobulin in sensitized LVAD recipients. Transplant Proc 1998;30:1110.

    Article  PubMed  CAS  Google Scholar 

  45. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999;100:II229.

    PubMed  CAS  Google Scholar 

  46. Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of cyclophos-phamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002;105:1214.

    Article  PubMed  CAS  Google Scholar 

  47. Aranda JM Jr, Scornik JC, Normann SJ, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 2002;73:907.

    Article  PubMed  Google Scholar 

  48. Garrett HE Jr, Groshart, K, Duvall-Seaman D, et al. Treatment of humoral rejection with rituximab. Ann Thorac Surg 2002;74:1240.

    Article  PubMed  Google Scholar 

  49. Renlund DG, Taylor DO, Kfoury AG, Shaddy RS. New UNOS rules: historical background and implications for transplantation management. United Network for Organ Sharing. J Heart Lung Transplant 1999;18:1065.

    Article  PubMed  CAS  Google Scholar 

  50. Kauffman HM, McBride MA, Shield CF, et al. Determinants of waiting time for heart transplants in the United States. J Heart Lung Transplant 1999;18:414.

    Article  PubMed  CAS  Google Scholar 

  51. Data from the Organ Procurement and Transplantation Network Web site at http://www.optn.org/latestData/stateData.asp?type=region.

  52. Whellan DJ, Tudor G, Denofrio D, et al. Heart transplant center practice patterns affect access to donors and survival of patients classified as status 1 by the United Network of Organ Sharing. Am Heart J 2000; 140:443.

    Article  PubMed  CAS  Google Scholar 

  53. Laks H, Marelli D, Fonarow GC, et al. Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg 2003;125:49.

    Article  PubMed  Google Scholar 

  54. Data from the Organ Procurement and Transplantation Network Web site at http://www.optn.org/latestData/step2.asp.

  55. Chen EP, Bittner HB, Kendall SW, Van Trigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. Crit Care Med 1996;24:1352.

    Article  PubMed  CAS  Google Scholar 

  56. Shivalkar B, Van Loon J, Wieland W, et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 1993;87:230.

    PubMed  CAS  Google Scholar 

  57. Pinelli G, Mertes PM, Carteaux JP, et al. Myocardial effects of experimental acute brain death: evaluation by hemodynamic and biological studies. Ann Thorac Surg 1995;60:1729.

    Article  PubMed  CAS  Google Scholar 

  58. White M, Wiechmann RJ, Roden RL, et al. Cardiac beta-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury. Evidence for catecholamine-mediated myocardial damage. Circulation 1995;92:2183.

    PubMed  CAS  Google Scholar 

  59. Stoica SC, Goddard M, Large SR. The endothelium in clinical cardiac transplantation. Ann Thorac Surg 2002;73:1002.

    Article  PubMed  Google Scholar 

  60. Szabo G, Buhmann V, Bahrle S, et al. Brain death impairs coronary endothelial function. Transplantation 2002;73:1846.

    Article  PubMed  CAS  Google Scholar 

  61. Koo DD, Welsh KI, McLaren AJ, et al. Cadaver vs living donor kidneys: impact of donor factors on antigen induction before transplantation. Kidney Int 1999;56:1551.

    Article  PubMed  CAS  Google Scholar 

  62. Wilhelm MJ, Pratschke J, Beato F, et al. Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation 2000;102:2426–2433.

    PubMed  CAS  Google Scholar 

  63. Tsai FC, Marelli D, Bresson J, et al. Use of hearts transplanted from donors with atraumatic intracranial bleeds. J Heart Lung Transplant 2002;21:623.

    Article  PubMed  Google Scholar 

  64. Schnuelle P, Berger S, de Boer J, et al. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation 2001;72:455.

    Article  PubMed  CAS  Google Scholar 

  65. Chen JM, Cullinane S, Spanier TB, et al. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation 1999;100:II244.

    PubMed  CAS  Google Scholar 

  66. Chen EP, Bittner HB, Kendall SW, Van Trigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. Crit Care Med 1996;24:1352.

    Article  PubMed  CAS  Google Scholar 

  67. Hunt SA, Baldwin J, Baumgartner W, et al. Cardiovascular management of a potential heart donor: a statement from the Transplantation Committee of the American College of Cardiology. Crit Care Med 1996;24:1599.

    Article  PubMed  CAS  Google Scholar 

  68. Ozcan YA, Begun JW, McKinney MM. Benchmarking organ procurement organizations: a national study. Health Serv Res 1999;34:855.

    PubMed  CAS  Google Scholar 

  69. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28–29, 2001, Crystal City, Virginia. Circulation 2002;106:836.

    Article  PubMed  Google Scholar 

  70. Jeevanandam V, Furukawa S, Prendergast TW, et al. Standard criteria for an acceptable donor heart are restricting heart transplantation. Ann Thorac Surg 1996;62:1268.

    Article  PubMed  CAS  Google Scholar 

  71. Young JB, Naftel DC, Bourge RC, et al. Matching the heart donor and heart transplant recipient: clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. J Heart Lung Transplant 1994;13:353.

    PubMed  CAS  Google Scholar 

  72. Wheeldon DR, Potter CD, Oduro A, et al. Transforming the “unacceptable” donor: outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant 1995;14:734.

    PubMed  CAS  Google Scholar 

  73. Jahania MS, Sanchez JA, Narayan P, et al. Heart preservation for transplantation: principles and strategies. Ann Thorac Surg 1999;68:1983.

    Article  PubMed  CAS  Google Scholar 

  74. Demmy TL, Biddle JS, Bennett LE, et al. Organ preservation solutions in heart transplantation—patterns of usage and related survival. Transplantation 1997;63:262.

    Article  PubMed  CAS  Google Scholar 

  75. Hassanein WH, Zellos L, Tyrrell TA, et al. Continuous perfusion of donor hearts in the beating state extends preservation time and improves recovery of function. J Thorac Cardiovasc Surg 1998;116:821.

    Article  PubMed  CAS  Google Scholar 

  76. Nickless DK, Rabinov M, Richards SM, et al. Continuous perfusion improves preservation of donor rat hearts: importance of the implantation phase. Ann Thorac Surg 1998;65:1265.

    Article  PubMed  CAS  Google Scholar 

  77. Jones BU, Serna DL, Beckham G, et al. Recovery of cardiac function after standard hypothermic storage vs preservation with Peg-hemoglobin. ASAIO J 2001;47:197.

    Article  PubMed  CAS  Google Scholar 

  78. Shumway NE, Lower RR, Stouffer RC. Transplantation of the heart. Adv Surg 1966;2:265.

    PubMed  CAS  Google Scholar 

  79. Sarsam MA, Campbell CS, Yonan NA, et al. An alternative surgical technique in orthotopic cardiac transplantation. J Cardiac Surg 1993; 8:344.

    Article  CAS  Google Scholar 

  80. Dreyfus G, Jebara V, Mihaileanu S, et al. Total orthotopic heart transplantation: an alternative to the standard technique. Ann Thorac Surg 1991;52:1181.

    Article  PubMed  CAS  Google Scholar 

  81. Blanche C, Nessim S, Quartel, A, et al. Heart transplantation with bicaval and pulmonary venous anastomoses. A hemodynamic analysis of the first 117 patients. J Cardiovasc Surg 1997;38:561.

    CAS  Google Scholar 

  82. Aziz T, Burgess M, Khafagy R, et al. Bicaval and standard techniques in ortho-topic heart transplantation: medium-term experience in cardiac performance and survival. J Thorac Cardiovasc Surg 1999;118:115.

    Article  PubMed  CAS  Google Scholar 

  83. Milano CA, Shah AS, Van Trigt P, et al. Evaluation of early postoperative results after bicaval vs standard cardiac transplantation and review of the literature. Am Heart J 2000;140:717.

    Article  PubMed  CAS  Google Scholar 

  84. Aziz TM, Burgess MI, El-Gamel A, et al. Orthotopic cardiac transplantation technique: a survey of current practice. Ann Thorac Surg 1999;68:1242.

    Article  PubMed  CAS  Google Scholar 

  85. Kirklin JK, Naftel DC, Bourge RC, et al. Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study. J Thorac Cardiovasc Surg 2003;125:881.

    Article  PubMed  CAS  Google Scholar 

  86. Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. J Heart Lung Transplant 1993;12:549.

    PubMed  CAS  Google Scholar 

  87. Hosenpud J, Bennett L, Keck B, et al. The Registry of the International Society for Heart and Lung Transplantation: 17th Official Report—2000. J Heart Lung Transplant 2000; 19:909.

    Article  PubMed  CAS  Google Scholar 

  88. Asimakopoulos G, Smith PL, Ratnatunga CP et al. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg 1999; 68:1107.

    Article  PubMed  CAS  Google Scholar 

  89. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:552.

    Article  PubMed  CAS  Google Scholar 

  90. Wessel D, Adatia I, Giglia T, et al. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993;88:2128–2138.

    PubMed  CAS  Google Scholar 

  91. Bittner HB, Chen EP, Kendall SW, et al. Brain death alters cardiopulmonary hemodynamics and impairs right ventricular power reserve against an elevation of pulmonary vascular resistance. Chest 1997; 111:706.

    PubMed  CAS  Google Scholar 

  92. De Broux E, Lagace G, Dumont L, et al. Efficacy of dobutamine in the failing transplanted heart. J Heart Lung Transplant 1992; 11:1133.

    PubMed  Google Scholar 

  93. Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. Ann Thorac Surg 2002;73:325.

    Article  PubMed  Google Scholar 

  94. Vincent JL, Carlier E, Pinsky MR, et al. Prostaglandin El infusion for right ventricular failure after cardiac transplantation. J Thorac Cardiovasc Surg 1992;103:33.

    PubMed  CAS  Google Scholar 

  95. Kieler-Jensen N, Lundin S, Ricksten SE. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin El, and sodium nitroprusside. J Heart Lung Transplant 1995;14:436.

    PubMed  CAS  Google Scholar 

  96. Haraldsson A, Kieler-Jensen N, Ricksten S-E. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vase Anesth 1996;10:864.

    Article  CAS  Google Scholar 

  97. Rajek A, Pernerstorfer T, Kastner J, et al. Inhaled nitric oxide reduces pulmonary vascular resistance more than prostaglandin E(l) during heart transplantation. Anesth Analg 2000;90:523.

    Article  PubMed  CAS  Google Scholar 

  98. Chen JM, Levin HR, Rose EA, et al. Experience with right ventricular assist devices for perioperative right-sided circulatory failure. Ann Thorac Surg 1996;61:305.

    Article  PubMed  CAS  Google Scholar 

  99. Barnard SP, Hasan A, Forty J, et al. Mechanical ventricular assistance for the failing right ventricle after cardiac transplantation. Eur J Cardiothorac Surg 1995;9:297.

    Article  PubMed  CAS  Google Scholar 

  100. Kaul TK, Fields BL. Postoperative acute refractory right ventricular failure: incidence, pathogenesis, management and prognosis. Cardiovasc Surg 2000;8:l.

    Google Scholar 

  101. Albright TN, Zimmerman MA, Selzman CH. Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care 2002;11:326.

    PubMed  Google Scholar 

  102. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588.

    Article  PubMed  CAS  Google Scholar 

  103. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998;116:973.

    Article  PubMed  CAS  Google Scholar 

  104. Taylor DO. Cardiac transplantation: drug regimens for the 21st century. Ann Thorac Surg 2003;75:S72.

    Article  PubMed  Google Scholar 

  105. Valantine H. Neoral use in the cardiac transplant recipient. Transplant Proc 2000; 32:S27.

    Article  Google Scholar 

  106. Taylor DO, Barr ML, Meiser BM, et al. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. J Heart Lung Transplant 2001;20:734.

    Article  PubMed  CAS  Google Scholar 

  107. Opelz G. Multicenter evaluation of immunosuppressive regimens in heart transplantation. Transplant Proc 1997;29:617.

    Article  PubMed  CAS  Google Scholar 

  108. Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporin A. Ann NY Acad Sci 1993;696:9.

    Article  PubMed  CAS  Google Scholar 

  109. Kobashigawa JA. Controversies in heart and lung transplantation immuno-suppression: tacrolimus vs cyclosporine. Transplant Proc 1998;30:1095.

    Article  PubMed  CAS  Google Scholar 

  110. Allison AC, Kowalski WJ, Muller CD, et al. Mechanism of action of myco-phenolic acid. Ann NY Acad Sci 1990;696:63.

    Article  Google Scholar 

  111. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998;66:507–515.

    Article  PubMed  CAS  Google Scholar 

  112. Hosenpud JD, Bennett LE. Mycophenolate mofetil vs azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 2001;72:1662.

    Article  PubMed  CAS  Google Scholar 

  113. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253.

    Article  PubMed  CAS  Google Scholar 

  114. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001;59:3.

    Article  PubMed  CAS  Google Scholar 

  115. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847.

    Article  PubMed  CAS  Google Scholar 

  116. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48.

    Article  PubMed  CAS  Google Scholar 

  117. Prieto M, Lake KD, Pritzker MR, et al. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients. J Heart Lung Transplant 1991;10:901.

    PubMed  CAS  Google Scholar 

  118. Miller LW, Wolford T, McBride LR, et al. Successful withdrawal of cortico-steroids in heart transplantation. J Heart Lung Transplant 1992; 11(2 part 2):431.

    PubMed  CAS  Google Scholar 

  119. Olivari MT, Jessen ME, Baldwin BJ, et al. Triple-drug immunosuppression with steroid discontinuation by 6 months after heart transplantation. J Heart Lung Transplant 1995;14(1 part 1):127.

    PubMed  CAS  Google Scholar 

  120. Kobashigawa JA, Stevenson LW, Brownfield ED, et al. Corticosteroid weaning late after heart transplantation: relation to HLA-DR mismatching and long-term metabolic benefits. J Heart Lung Transplant 1995;14:963.

    PubMed  CAS  Google Scholar 

  121. Taylor DO, Bristow MR, O’Connell JB, et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant 1996;15:1039.

    PubMed  CAS  Google Scholar 

  122. Taylor DO, Kfoury AG, Pisani B, et al. Antilymphocyte-antibody prophylaxis: review of the adult experience in heart transplantation. Transplant Proc 1997;29(suppl 8A):13S.

    Article  PubMed  CAS  Google Scholar 

  123. Norman DJ, Chatenoud L, Cohen D, et al. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 1993;25(2 suppl 1):89.

    PubMed  CAS  Google Scholar 

  124. Nashan B, Moore R, Amlot P. et al. Randomised trial of basiliximab vs placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997;350:1193.

    Article  PubMed  CAS  Google Scholar 

  125. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338:161.

    Article  PubMed  CAS  Google Scholar 

  126. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000;342:613.

    Article  PubMed  CAS  Google Scholar 

  127. Kirklin JK, Naftel DC, Bourge RC, et al. Rejection after cardiac transplantation: a time-related risk factor analysis. Circulation 1992;86(suppl II):II–236.

    Google Scholar 

  128. Kirlin JK, Naftel DC, Bourge RC, et al. Evolving trends in risk profiles and causes of death after heart transplantation: a 10-year multi-institutional study. J Thorac Cardiovasc Surg 2003;125:881.

    Article  Google Scholar 

  129. Valantine HA, Yeoh TK, Gibbons R, et al. Sensitivity and specificity of diastolic indexes for rejection surveillance: temporal correlation with endomyocardial biopsy. J Heart Lung Transplant 191;10(5 part 1):757.

    Google Scholar 

  130. Winters GL, Loh E, Schoen FJ. Natural history of focal moderate cardiac allograft rejection: is treatment warranted? Circulation 1995;91:1975.

    PubMed  CAS  Google Scholar 

  131. Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Lung Transplant 1989;8:430.

    CAS  Google Scholar 

  132. Rodriguez ER. The pathology of heart transplant biopsy specimens: revisiting the 1990 ISHLT working formulation. J Heart Lung Transplant 2003;22:3.

    Article  PubMed  Google Scholar 

  133. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 2001;20:316.

    Article  PubMed  CAS  Google Scholar 

  134. Garrett HE, Groshart K, Duvall-Seaman D, et al Treatment of humoral rejection with rituximab. Ann Thorac Surg 2002;74:1240.

    Article  PubMed  Google Scholar 

  135. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003;22:58.

    Article  PubMed  Google Scholar 

  136. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741.

    Article  PubMed  CAS  Google Scholar 

  137. Rubin RH. Prevention and treatment of cytomegalovirus disease in heart transplant recipients. J Heart Lung Transplant 2000;19:731.

    Article  PubMed  CAS  Google Scholar 

  138. Madden BP, Reynolds L, Tryhorn Y, et al. Is routine post-operative surveillance for cytomegalovirus infection following heart transplantation necessary? Eur J Cardiothorac Surg 1998;14:15.

    Article  PubMed  CAS  Google Scholar 

  139. Avery RK. Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients. Curr Opin Cardiol 1998;13:122.

    Article  PubMed  CAS  Google Scholar 

  140. Koskinen PK, Kallio EA, Tikkanen JM. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1999;1:115.

    Article  PubMed  CAS  Google Scholar 

  141. Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyper-immune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir vs ganciclovir alone. Transplantation 2001;72:1647.

    Article  PubMed  CAS  Google Scholar 

  142. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant 1992;11(3 part 2):S38.

    PubMed  CAS  Google Scholar 

  143. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 1998;17:744.

    PubMed  CAS  Google Scholar 

  144. Rickenbacher PR, Pinto FJ, Chenzbraun A, et al. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol 1995;25:171.

    Article  PubMed  CAS  Google Scholar 

  145. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621.

    Article  PubMed  CAS  Google Scholar 

  146. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a 4-year randomized trial. Circulation 1997;96:1398.

    PubMed  CAS  Google Scholar 

  147. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847.

    Article  PubMed  CAS  Google Scholar 

  148. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108:48.

    Article  PubMed  CAS  Google Scholar 

  149. Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated atherosclerosis: a randomized trial. Lancet 2002;359:1108.

    Article  PubMed  CAS  Google Scholar 

  150. Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl JMed 1993;328:164.

    Article  CAS  Google Scholar 

  151. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990;323:1767.

    Article  PubMed  CAS  Google Scholar 

  152. Penn I. Solid tumors in cardiac allograft recipients. Ann Thorac Surg 1995; 60:1559.

    Article  PubMed  CAS  Google Scholar 

  153. Rinaldi M, Pellegrini C, D’Armini AM, et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 2001;19:696.

    Article  PubMed  CAS  Google Scholar 

  154. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173.

    PubMed  CAS  Google Scholar 

  155. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant recipients: 10 years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991;10:877.

    PubMed  CAS  Google Scholar 

  156. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990;323:1723.

    Article  PubMed  CAS  Google Scholar 

  157. Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 195;46:381.

    Google Scholar 

  158. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995;20:1346.

    PubMed  CAS  Google Scholar 

  159. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP Task Force and the Naymo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517.

    Article  PubMed  CAS  Google Scholar 

  160. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995;86:3333.

    PubMed  CAS  Google Scholar 

  161. Zilz ND, Olson LJ, McGregor CG. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001;20:770.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medicine School, Boston

    John Adams Jarcho MD & James C. Fang MD

  2. UpToDate Inc., Wellesley, MA

    John Adams Jarcho MD

Authors
  1. John Adams Jarcho MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James C. Fang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    James C. Fang MD  & Gregory S. Couper MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humama Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Jarcho, J.A., Fang, J.C. (2005). Recent Advances in Cardiac Allotransplantation. In: Fang, J.C., Couper, G.S. (eds) Surgical Management of Congestive Heart Failure. Contemporary Cardiology. Humana Press. https://doi.org/10.1385/1-59259-842-0:001

Download citation

  • DOI: https://doi.org/10.1385/1-59259-842-0:001

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-034-2

  • Online ISBN: 978-1-59259-842-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation